Navigation Links
Sinobiomed Directors Confirm Hiring of New Chief Financial Officer
Date:10/8/2008

SHANGHAI, China, Oct. 8 /PRNewswire-FirstCall/ -- Sinobiomed Inc. ("Sinobiomed", or "the Company") (OTC Bulletin Board: SOBM) is pleased to announce that its Board of Directors voted on October 2, 2008 to officially appoint Lionel Choong as the Company's Chief Financial Officer under a Corporate Consulting Services Agreement to be effective as of September 1, 2008. In addition, Mr. Choong has been appointed to the Company's audit committee. An earlier news release dated August 13, 2008 that first announced the hiring can be viewed on the Company website. (http://www.sinobiomed.com).

As CFO, Mr. Choong will oversee the Company's various financial functions, including finance and accounting, financial planning and analysis, regulatory and risk management, and facilities development. He will also be involved with other corporate activities working with the Company's CEO, Banyun Yang, to develop strategies and tactics for long-term growth.

ABOUT SINOBIOMED INC.

Sinobiomed Inc. is a leading Chinese developer of genetically engineered recombinant protein drugs and vaccines. Based in Shanghai, Sinobiomed currently has 10 products approved or in development: three on the market, four in clinical trials and three in research and development. The Company's products respond to a wide range of diseases and conditions, including: malaria, hepatitis, surgical bleeding, cancer, rheumatoid arthritis, diabetic ulcers and burns, and blood cell regeneration.

SINOBIOMED INC.

LANE 4705, NO. 58, NORTH YANG GAO RD.

PUDONG, NEW AREA SHANGHAI, 201206 CHINA

PHONE: 86-58993708 / FAX: 86-58993709

INVESTOR RELATIONS

PHONE: 1-718-502-8801 TOLL FREE: 1-866-588-0829

EMAIL: INFO@SINOBIOMED.COM

FORWARD LOOKING STATEMENTS This news release may include "forward-looking

statements" regarding Sinobiomed, and its subsidiaries, business and project plans. Such forward looking statements are within the meaning of Section 27A of the Securities Act of 1933, as amended, and section 21E of the United States Securities and Exchange Act of 1934, as amended, and are intended to be covered by the safe harbor created by such sections. Where Sinobiomed expresses or implies an expectation or belief as to future events or results, such expectation or belief is believed to have a reasonable basis. However, forward-looking statements are subject to risks, uncertainties and other factors, which could cause actual results to differ materially from future results expressed, projected or implied by such forward-looking statements. Sinobiomed does not undertake any obligation to update any forward looking statement, except as required under applicable law.


'/>"/>
SOURCE Sinobiomed Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. HealthInsuranceFinders.com Launches Video Contest for Young Directors
2. Arrow International Urges Shareholders To Vote for Approval of the $45.50 Teleflex Inc. Merger and for the Current Board of Directors
3. Zimmer Holdings Offer and ORTHOsoft Directors Circular Mailed to Shareholders
4. Glass Lewis Recommends Arrow Shareholders Vote on the White Proxy Card for Merger With Teleflex and for Current Board of Directors at Arrow Annual Meeting
5. STERIS Corporation Board of Directors Names Walter M. Rosebrough Jr. President and Chief Executive Officer
6. Patient Safety Authority Board of Directors Names Infection Advisory Panel
7. William Moore Appointed to IRIDEX Board of Directors
8. Arrow International Sends Letter Reminding Shareholders to Vote White Proxy Card in Support of Teleflex Merger and Election of Current Board of Directors
9. MAKO Surgical Corp. Names Frederic H. Moll, M.D. to Board of Directors
10. Jon R. Wampler Joins Portico Systems Board of Directors
11. Lorus Therapeutics announces election of three new Directors and appoints a new Chairman
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... The temporary closing of Bruton Memorial Library ... City Observer , brings up a new, often overlooked aspect of head lice: the parasite’s ... for fumigation is not a common occurrence, but a necessary one in the event that ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, ... and his M.D from the David Geffen School of Medicine at UCLA. He trained ... Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where ...
(Date:6/25/2016)... ... ... Conventional wisdom preaches the benefits of moderation, whether it’s a matter of ... too high can result in disappointment, perhaps even self-loathing. However, those who set the ... Research from PsychTests.com reveals that behind the tendency to set low expectations ...
(Date:6/24/2016)... ... 2016 , ... June 19, 2016 is World Sickle Cell Observance Day. In ... benefits of holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued ... Sickle Cell Disease (SCD) is a disorder of the red blood cells, which can ...
(Date:6/24/2016)... ... 2016 , ... Global law firm Greenberg Traurig, P.A. announced that 20 Florida ... their peers for this recognition are considered among the top 2 percent of lawyers ... as members of this year’s Legal Elite Hall of Fame: Miami Shareholders Mark ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... Dehaier Medical Systems Ltd. (NASDAQ: ... and sells medical devices and wearable sleep respiratory products ... cooperation agreement with Hongyuan Supply Chain Management Co., Ltd. ... 20, 2016, to develop Dehaier,s new Internet medical technology ... will leverage Hongyuan Supply Chain,s sales platform to reach ...
(Date:6/24/2016)... -- According to a new market research ... Safety Pen Needles), Needle Length (4mm, 5mm, 6mm, 8mm, ... Purchase (Retail, Non-Retail) - Trends & Global Forecasts to ... for the forecast period of 2016 to 2021. This ... 2021 from USD 1.65 Billion in 2016, growing at ...
(Date:6/24/2016)... KNOXVILLE, Tenn. , June 24, 2016 /PRNewswire/ ... market providing less invasive and more durable cerebrospinal ... million in funding.  The Series-A funding is led ... the Lighthouse Fund, and other private investors.  Arkis, ... less-invasive neurosurgical instrumentation and the market release of ...
Breaking Medicine Technology: